Our partners Gil Zhang, Diana Li, Muran Sun, Yongqi Tao and Huihui LI have authored the China chapter of the newly released Chambers Global Practice Guides – Healthcare AI 2025.
The Guide provides up-to-date commentary and analysis on the legal framework for and regulatory oversight of healthcare AI, the nature of liability and risk in the sector, ethical and governance considerations, data privacy and protection, product liability, IP issues, future trends and regulatory developments, and practical considerations for healthcare AI developers and users.
In the Law & Practice section, our partners provide a detailed analysis of the legal landscape of healthcare AI in China, which include use of healthcare AI, legal framework for healthcare AI, regulatory oversight of healthcare AI, liability and risk in healthcare AI, Ethical and governance considerations for healthcare AI, data governance in healthcare AI, intellectual property issues regarding healthcare AI, and other related subjects, while in the Trends & Developments section, they examine market and industry trends and share insights into IP protection in this evolving sector.
Fangda has formed a special multi-disciplinary team to deal with many complex and cutting-edge issues in the AI market, from regulator hurdles, IP protection, market entry, corporate restructuring, data governance to product liability, litigation and unfair competition as a result of data distillation and AI training.
Anyone looking to understand the developments and trends in China’s healthcare AI sector can read online for free here: https://lnkd.in/gXD3MuGw The China chapter was first published in Chambers – Healthcare AI 2025.
